DEXCOM INC's ticker is DXCM and the CUSIP is 252131107. A total of 932 filers reported holding DEXCOM INC in Q2 2023. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DT Investment Partners, LLC | 64 | $7,808 | 0.00% |
| JFS WEALTH ADVISORS, LLC | 68 | $8,739 | 0.00% |
| PARNASSUS INVESTMENTS, LLC | 2,534 | $325,644 | 0.00% |
| WOLVERINE TRADING, LLC | 7,798 | $997,676 | 0.00% |
| Beacon Capital Management, LLC | 16 | $2,056 | 0.00% |
| TSFG, LLC | 24 | $3 | 0.00% |
| Allworth Financial LP | 1,069 | $137,378 | 0.00% |
| PITTENGER & ANDERSON INC | 120 | $15,422 | 0.00% |
| ClariVest Asset Management LLC | 16 | $2 | 0.00% |
| D. E. Shaw & Co., Inc. | 2,500 | $321,275 | 0.00% |
| JANICZEK WEALTH MANAGEMENT, LLC | 13 | $1,671 | 0.00% |
| EARNEST PARTNERS LLC | 132 | $16,963 | 0.00% |
| GW&K Investment Management, LLC | 115 | $15 | 0.00% |
| Koesten, Hirschmann & Crabtree, INC. | 1 | $190 | 0.00% |
| TD AMERITRADE INVESTMENT MANAGEMENT, LLC | 24 | $3 | 0.00% |
| Cutler Group LLC / CA | 500 | $2 | 0.00% |
| SOA Wealth Advisors, LLC. | 4 | $514 | 0.00% |
| Centerpoint Advisors, LLC | 4 | $1 | 0.00% |
| Parallax Volatility Advisers, L.P. | 60 | $7,711 | 0.00% |
| Colonial Trust Advisors | 29 | $3,727 | 0.00% |
About DEXCOM INC
Dexcom Inc. is a medical device company that specializes in continuous glucose monitoring (CGM) systems for people with diabetes. The company's CGM systems provide real-time glucose readings, allowing patients to better manage their diabetes and avoid dangerous blood sugar fluctuations.
Dexcom's CGM systems have been well-received by the diabetes community, with many patients reporting improved glucose control and quality of life. The company's latest product, the Dexcom G6, is a small, wearable device that provides continuous glucose readings without the need for fingersticks.
In addition to its innovative products, Dexcom has also been successful in forging partnerships with other companies in the diabetes space. For example, the company has teamed up with insulin pump manufacturer Tandem Diabetes Care to create an integrated system that allows patients to control their insulin delivery and glucose monitoring with a single device.
Despite its success, Dexcom faces challenges in the highly competitive diabetes market. The company must continue to innovate and improve its products in order to stay ahead of competitors like Abbott Laboratories and Medtronic.
Overall, Dexcom's focus on improving the lives of people with diabetes through innovative technology has made it a leader in the CGM market. As the company continues to grow and expand its offerings, it will likely remain a key player in the fight against diabetes.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists DEXCOM INC's shareholders in Q2 2023. To view DEXCOM INC's shareholder history, click here.